Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 6/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.56 |
| ▸ | JAK3 | P52333 | 8/20 | 0.41 |
| ▸ | JAK2 | O60674 | 7/20 | 0.41 |
| ▸ | JAK1 | P23458 | 6/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21066969 | 0.91 | MAPK8 (0.49) | MAPK8MAPK9JAK3JAK2JAK1 | |
| SCHEMBL16932224 | 0.79 | MAPK8 (0.60) | MAPK8MAPK9JAK3JAK2JAK1 | |
| SCHEMBL13735566 | 0.76 | MAPK8 (0.57) | MAPK8MAPK9JAK3JAK2JAK1 | |
| SCHEMBL21066961 | 0.75 | MAPK8 (0.49) | MAPK8MAPK9JAK3JAK2JAK1 | |
| SCHEMBL27949559 | 0.75 | MAPK8 (0.49) | MAPK8MAPK9JAK3JAK2JAK1 | |
| SCHEMBL13734783 | 0.75 | MAPK8 (0.56) | MAPK8MAPK9JAK3JAK2JAK1 | |
| SCHEMBL30801500 | 0.75 | MAPK8 (0.56) | MAPK8MAPK9JAK3JAK2JAK1 | |
| SCHEMBL21066964 | 0.75 | MAPK8 (0.44) | MAPK8MAPK9JAK3JAK2JAK1 | |
| SCHEMBL13735202 | 0.74 | MAPK8 (0.55) | MAPK8MAPK9JAK3JAK2JAK1 | |
| SCHEMBL21066971 | 0.74 | MAPK8 (0.53) | MAPK8MAPK9SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190194144-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194144-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | MAPK8 45/4885MAPK9 87/4885JAK3 842/4885 |
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | MAPK8 45/4885MAPK9 87/4885JAK3 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.